AEM vs FUL

AEM's deterministic health score is concerning with a Piotroski F-Score of 4/9, indicating marginal financial stability, while the absence of an Altman Z-Score limits distress risk assessment. Despite strong profitability metrics—ROE of 15.67%, gross margin of 70.24%, and robust earnings growth of 85.8% YoY—the stock trades at a premium valuation (P/E 31.23 vs sector avg 25.89) above both the Graham Number ($85.07) and intrinsic value estimate ($202.66). Strong recent price performance (+145% 1Y) and analyst buy recommendation are counterbalanced by weak technical trend (10/100) and limited insider sentiment (40/100). The balance between operational strength and valuation concerns leads to a neutral stance.

H.B. Fuller exhibits strong fundamental health with a Piotroski F-Score of 7/9, indicating robust operational efficiency. While the current price of $62.83 sits above the Graham Number ($49.65), it remains well below the growth-based intrinsic value of $85.26. The company is experiencing a divergence between declining revenue (-2.30%) and surging earnings growth (58.30%), suggesting significant margin expansion or cost optimization. Despite a bearish technical trend, the attractive forward P/E of 12.22 and analyst buy ratings support a positive outlook.